24/7 Customer Support

Automated Insulin Delivery Market

By System Architecture (Hybrid Closed Loop, Fully Closed Loop, Predictive Low-Glucose Suspend); Pump Form Factor (Tubed Pump, Patch/Tubeless Pump); Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational and Other); Revenue Component (Pump Hardware, Disposables and Consumables, Algorithm/Software Subscription); End User (Home Use, Hospital Inpatient, Long-Term Care); Age Group (Pediatric (under 12), Adolescent (12–18), Adult (18–65), Older Adult (65+)); Distribution Channel (Pharmacy Benefit, Durable Medical Equipment Channel, Direct-to-Consumer, Hospital and Institutional Tender)—Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026–2035

Last Updated: 20 Nov 2026 |Report ID: AA11262057|Category: Health Care Equipment & Services|Format: PDF|Pages: 260

FREQUENTLY ASKED QUESTIONS

The global automated insulin delivery market was valued at USD 6 billion in 2025 and is projected to reach USD 20.4 billion by 2035, growing at a CAGR of 13.0% over the forecast period 2026–2035.

Miniaturized tubeless patch pumps integrated with predictive AI algorithms dominate.

Expanded Medicare coverage accelerates adoption by drastically reducing out-of-pocket patient costs.

North America leads, driven by high diagnostic rates and robust medical infrastructure.

Non-traditional tech firms entering the continuous glucose monitoring space disrupt legacy manufacturers.

Stringent FDA clinical trial requirements for closed-loop software systems present high barriers.

LOOKING FOR COMPREHENSIVE MARKET KNOWLEDGE? ENGAGE OUR EXPERT SPECIALISTS.

SPEAK TO AN ANALYST